Gregory A. Castanias (Greg)

Partner

Greg Castanias is an appellate and intellectual property litigator with extensive Supreme Court and Federal Circuit advocacy experience. He heads Jones Day's Federal Circuit practice.

Greg’s recent Federal Circuit victories as an oral advocate include Association for Molecular Pathology v. Myriad Genetics (2011), upholding the patent-eligibility of isolated human genes; Haemonetics v. Fenwal (2010), reversing a $16 million verdict and injunction; Transocean v. Maersk (2010), making important law on the meaning of “sale” and “offer for sale”; Vizio v. USITC (2010), reversing an ITC exclusion order as a matter of law; LabCorp v. Metabolite (2010 (transferring case to 10th Circuit) and 2011 (10th Cir.)), a successful declaratory-judgment action ending this long-running intellectual-property dispute; Martek v. Nutrinova (2009), an across-the-board win in a four-patent biotechnology dispute before a rare five-judge panel; Finisar v. DIRECTV Group (2008 and 2010), reversing a $129 million adverse patent-infringement judgment, followed by a later appeal affirming the claims’ invalidity; Ball Aerosol v. Limited Brands (2009), reversing a multimillion-dollar patent-infringement judgment, as a matter of law; and Kyocera Wireless v. USITC (2008), a pathbreaking decision limiting the ITC’s exclusionary authority.

Other recent clients have included Abbott, Apple, DePuy Spine, Eastman Chemical, Hoffmann-La Roche, IBM, Illumina, MathWorks, Merial, Pfizer, Procter & Gamble, SanDisk, SAP, Sercel, and SiRF.

The Legal 500 singled out Greg as one of the leading U.S. IP lawyers, calling him "a sharp and effective advocate who picks up the details of the matter quickly" and "a great issue-spotter and skilled advocate."